Shanghai September 19th 2019, Elpiscience Biopharma, Ltd., a clinical stage immuno-oncology company, announced that it will present data of anti-CD39 and anti-SIRPα antibodies, 欧洲杯买球网 and ES004, at the upcoming SITC conference which will be held from Nov. 7-10, 2019 in Washington DC.
欧洲杯买球网 is a potentially best-in-class anti-CD39 therapeutic antibody, which reverses the suppressive tumor microenvironment and demonstrates strong anti-tumor efficacy in preclinical models. Mechanistic study revealing a dependency on innate immune cells in 欧洲杯买球网-mediated anti-tumor response will be presented.
ES004 presentation will provide preclinical data on 2 unique anti-SIRPα antibodies, ES004-B4 and ES004-N4, which are CD47-SIRPα interaction “blocker” and “non-blocker”, respectively. Both antibodies greatly enhance macrophage-mediated tumor cell destruction, yet through different mechanisms of actions.
Details of the poster presentations are as follows:
|
Poster # P271 Title: Anti-SIRPalpha antibodies exert anti-tumor activity in both CD47-dependent and CD47-independent manners |
|
Date: Friday, Nov. 8, 2019, 7:00 am - 8:00 pm |
Corporate Communications:
PR@elpiscience.com
Partnering:
BD@elpiscience.com
